Skip to content

Overview

The Start-Up Innovation Catalyst is the startup program of the Longevity Investors Conference (LIC), organized by Longevity Investors in Gstaad, Switzerland. Up to 9 carefully selected companies present their ideas, values and progress in front of leading longevity investors.

Selected startups either join an existing main-stage panel as a real-world case study or give a focused presentation within the main agenda. Packages include conference access, accommodation in Gstaad, curated investor networking, and promotion on the conference website, brochure, newsletter and YouTube.

Participation is paid: the listed packages are CHF 8,000 and CHF 6,000, excluding 8.1% VAT and a 2.95% service fee. Past catalyst companies include BioXtek, Gero.ai and CellRep.

Who it is for

Longevity startups with a strong science base and investment case. The page does not publish formal eligibility rules.

Check if you are eligible

Check your eligibility for LIC Start-Up Innovation Catalyst

Admissions and application

Apply through the Catalyst page. Up to 9 companies are selected; for 2026 the first selection was announced in early July. No 2027 call is published.

Benefits

  • A main-stage panel slot or a focused presentation to a curated investor audience.
  • Full conference access and investor networking.
  • Accommodation in Gstaad (3 nights at the Bernerhof in one package) and meals including the gala dinner.
  • Promotion on the website, brochure, newsletter, social media and YouTube, plus a session recording.

Timeline

Annual, tied to LIC in Gstaad. For 2026, the first selection was announced in early July. The 2027 timeline is not published.

What came of it

Past catalyst companies listed include BioXtek, Gero.ai and CellRep, and others citing raises from USD 12.9M to USD 37M.

How to go about it

  1. Read what it asks for

    Who can apply, how people get in and whether it is open right now.

  2. Have something to show

    Programs pick people whose work they can already point to. Put yours where it can be found.

  3. Apply the way the program asks

    The program has not published how to apply. Terms and dates change. Check the official page before you act.

What it pays

Pay to participate: packages listed at CHF 8,000 and CHF 6,000, plus 8.1% VAT and a 2.95% service fee. No investment is made by the organizer.

Questions about this program

What is the LIC Start-Up Innovation Catalyst?

The startup showcase of the Longevity Investors Conference in Gstaad, where up to 9 selected longevity startups present to investors.

Does it cost money?

Yes. Packages are listed at CHF 8,000 and CHF 6,000, plus 8.1% VAT and a 2.95% service fee.

What formats are offered?

Joining an existing main-stage panel as a case study, or a focused presentation within the main agenda.

What is included?

Conference access, accommodation in Gstaad, meals including the gala dinner, investor networking and promotion.

How many startups are selected?

Up to 9.

Is it open now?

The 2026 selection was in July; no 2027 call is published.

Does the organizer invest?

No investment is mentioned; it is a paid showcase.

Which companies have taken part?

Examples listed include BioXtek, Gero.ai and CellRep.

About Longevity Investors

Connecting investors in longevity science.

Lists that include this program

From public sources

What the sources say about LIC Start-Up Innovation Catalyst

The Longevity Show Pitch Competition logoCompetition

Exceptional Ventures

A pitch competition for consumer-facing longevity startups at The Longevity Show in London, run with Exceptional Ventures.

Location
London, UK
Terms
No Compensation

Superscout Pro

Find faster. Show up verified. Keep your deals private.

$99a year, or $12 a month
Get Pro
  • Search that narrowsInvestors, programs, accelerators, incubators and studios, by stage, sector and place.
  • A verified profileThe people you reach know you are who you say you are.
  • A private deal vaultThe startups you are watching, with your notes and your reasons. Nobody else's eyes.

Is this page right?Reviewed · How the research works

Something's off